Botulism

Pathophysiology

• Botulinum toxin acts by inhibiting the release of acetylcholine at the neuromuscular junction, preventing neurotransmission and resulting in flaccid paralysis, with an estimated lethal dose for a 70-kg adult of 70 μg when ingested orally, and it enters the vascular circulation and is transported to peripheral cholinergic nerve terminals, where it binds to neuronal cell receptors, followed by receptor-mediated endocytosis, translocation to the cytosol, and enzymatic activity that cleaves specific proteins involved in the release of acetylcholine 1

Clinical Presentation and Diagnosis

• Infant botulism typically presents with descending flaccid paralysis, and diagnosis is based on clinical presentation, history of exposure to risk factors such as honey consumption, and laboratory confirmation through detection of botulinum toxin in stool or serum 1

Treatment and Prevention

• The Centers for Disease Control and Prevention recommends supportive care, including respiratory support if needed, and administration of Botulism Immune Globulin Intravenous (BabyBIG), which contains antibodies that bind to and neutralize circulating botulinum toxin, and prevention of infant botulism primarily involves avoiding feeding honey to infants under 12 months of age, as honey is a known source of C. botulinum spores that can germinate in the infant gut 1

Epidemiology

• Seven antigenically distinct botulinum toxins have been identified (A, B, C, D, E, F, and G), with types A, B, E, and rarely F causing human disease, and types A and B being the most common serotypes in infant botulism 1

Adverse Effects and Management

• Botulinum toxin can cause Horner syndrome by spreading from the injection site to nearby anatomical structures containing sympathetic nerve fibers, interrupting the oculosympathetic pathway, characterized by the classic triad of ptosis, miosis, and anhidrosis, although anhidrosis may be absent in incomplete cases, and the risk can be increased by injections in anatomically close zones to the cervical sympathetic pathway, diffusion of the medication during the critical 24-48 hours after injection, high doses of botulinum toxin, and inadequate injection technique 1
• To minimize the risk of Horner syndrome and other adverse effects, it is recommended to use the minimum effective dose, apply precise injection technique, avoid massaging the treated area after injection, and keep the patient in a vertical position for 3-4 hours after treatment, as supported by medical guidelines 1
• Post-administration care for patients receiving botulinum toxin should include remaining upright for 3-4 hours after treatment, avoiding touching or massaging treated areas, refraining from strenuous exercise for 24 hours, and avoiding alcohol consumption for 24 hours, as advised by medical experts 2
• The administration of botulinum toxin carries a 1-2% risk of anaphylaxis, and epinephrine and antihistamines should be available during administration, as recommended by medical guidelines 2
• The use of a skin-vibrating device, cold air skin cooling, or topical anesthetics may help decrease the pain of botulinum toxin injection, as suggested by the American Academy of Dermatology 3
• Early recognition of symptoms, evaluation to rule out other potentially serious causes, follow-up until complete resolution of symptoms, and documentation of the event to adjust dose and technique in future applications are crucial, with most cases being self-limiting and resolving completely without specific medical intervention 1